Diamedica Therapeutics Stock Beneish M Score
| DMAC Stock | USD 4.62 0.08 1.70% |
DiaMedica | Beneish M Score |
At this time, it appears that DiaMedica Therapeutics is an unlikely manipulator. The earnings manipulation may begin if DiaMedica Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by DiaMedica Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of DiaMedica Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.88
Beneish M Score - Unlikely Manipulator
DiaMedica Therapeutics Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if DiaMedica Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 387.4 K | 369 K |
|
| |||||
| Total Assets | 56.9 M | 54.2 M |
|
| |||||
| Total Current Assets | 56.4 M | 53.7 M |
|
| |||||
| Non Current Assets Total | 638.8 K | 485 K |
|
| |||||
| Property Plant Equipment | 676.2 K | 644 K |
|
| |||||
| Depreciation And Amortization | 28.5 K | 30 K |
|
| |||||
| Selling General Administrative | 8.6 M | 8.2 M |
|
| |||||
| Total Current Liabilities | 2.9 M | 2.8 M |
|
|
DiaMedica Therapeutics Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between DiaMedica Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards DiaMedica Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find DiaMedica Therapeutics' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About DiaMedica Therapeutics Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Total Assets |
|
DiaMedica Therapeutics Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as DiaMedica Therapeutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Receivables | 823K | 340K | 130K | 82K | 369K | 387.5K | |
| Total Assets | 9.1M | 28.1M | 45.6M | 34.4M | 54.2M | 56.9M | |
| Total Current Assets | 8.8M | 27.9M | 45.4M | 33.8M | 53.7M | 56.4M | |
| Non Current Assets Total | 217K | 174K | 112K | 560K | 485K | 638.8K | |
| Property Plant Equipment | 217K | 74K | 112K | 560K | 644K | 676.2K | |
| Depreciation And Amortization | 877K | 21K | 24K | 25K | 30K | 28.5K | |
| Selling General Administrative | 3.7M | 4.4M | 4.9M | 6.2M | 8.2M | 8.6M | |
| Total Current Liabilities | 1.3M | 2.0M | 1.5M | 2.2M | 2.8M | 2.9M | |
| Non Current Liabilities Total | 118K | 53K | 3K | 400K | 317K | 158.5K | |
| Net Debt | (3.7M) | (7.3M) | (4.7M) | (4.3M) | (4.1M) | (4.4M) | |
| Short Term Debt | 60K | 130K | 98K | 138K | 166K | 90.0K | |
| Operating Income | (11.6M) | (12.7M) | (13.6M) | (14.0M) | (21.3M) | (20.2M) | |
| Total Cash From Operating Activities | (9.1M) | (9.2M) | (12.3M) | (11.5M) | (18.7M) | (17.8M) | |
| Short Term Investments | 4.0M | 20.1M | 40.4M | 28.8M | 48.4M | 50.8M |
DiaMedica Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DiaMedica Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DiaMedica Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
About DiaMedica Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DiaMedica Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DiaMedica Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DiaMedica Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out DiaMedica Therapeutics Piotroski F Score and DiaMedica Therapeutics Altman Z Score analysis. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.